Across TCGA pan-cancer cohorts, UBE2L3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBE2L3 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UBE2L3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated UBE2L3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where UBE2L3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.554	0.335	.009	16	view →
GBM	DFS	Quartile	All	0.599	0.812	.004	15	view →
LSCC	DFS	Tertile	II,III,IV	0.941	0.247	.006	10	view →
CCRCC	DFS	Median	II,III,IV	0.786	0.604	.031	3	view →
LUAD	OS	Quartile	All	1.000	0.918	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: UBE2L3 tumor-vs-normal RNA expression · all UBE2L3 data types